The existence of the blood-brain barrier (BBB) restricts the entry of drugs from the circulation
into the central nervous system (CNS), which severely affects the treatment of neurological …

Although the global prevalence of neurological disorders such as Parkinson's disease,
Alzheimer's disease, glioblastoma, epilepsy, and multiple sclerosis is steadily increasing …

Despite the increasing global incidence of brain disorders, achieving sufficient delivery
towards the central nervous system (CNS) remains a formidable challenge in terms of …

While the intranasal administration of drugs to the brain has been gaining both research
attention and regulatory success over the past several years, key fundamental and …

Intranasal drug delivery is emerging as a reliable and promising pathway to deliver a wide
range of therapeutic agents including small and large molecules, peptides and proteins …

In order to overcome the formidable challenges posed by the intricate physiological barriers
of the brain, the employment of intranasal administration (INA) has emerged as an …

The intranasal pathway, with its inherent virtues of circumvention of blood-brain barrier,
evasion of hepatic/first-pass metabolism, noninvasiveness, and ease of administration, has …

We overviewed the anatomy and physiology of the nose-to-brain pathway, along with the
mechanisms involved. We then summarized the interaction process between nanoparticles …

Background: Current cerebral drug delivery to the brain and Cerebrospinal Fluid (CSF) is
limited by the Blood-Brain Barrier (BBB) or the blood-blood Cerebrospinal Fluid (CSF) …

Alzheimer's disease (AD) is one of the neurological ailments which continue to represent a
major public health challenge, owing to increased life expectancy and aging population …